Correlation of high density lipoprotein cholesterol with resistance of epidermal growth factor receptor-tyrosine kinase inhibitor in advanced non-small-cell lung cancer
10.3760/cma.j.issn.1006-9801.2015.10.001
- VernacularTitle:晚期非小细胞肺癌患者血清高密度脂蛋白胆固醇水平与表皮生长因子受体酪氨酸激酶抑制剂耐药的相关性研究
- Author:
Yang LYU
;
Liyun MIAO
;
Xuansheng DING
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
High density lipoprotein cholesterol;
Epidermal growth factor;
Tyrosine kinase inhibitors;
Molecular targeted therapy;
Drug resistance,neoplasm
- From:
Cancer Research and Clinic
2015;27(10):649-654
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the relevance of high density lipoprotein cholesterol (HDL-C) level and resistance of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced non-small cell lung cancer (NSCLC).Methods In a total of 87 NSCLC patients harboring EGFR mutation treated with EGFR-TKI, the correlations of pre-treatment levels of soluble HDL-C between efficacy and resistance of EGFR-TKI were analyzed by Kaplan-Meier method and Cox proportional hazard model.Results Patients with normal HDL-C (≥0.94 mmol/L) had a better disease control rate (DCR) than those with low HDL-C (＜0.94 mmol/L) [94.5 ％ (52/55) vs 65.7 ％ (21/32), P ＜ 0.001].The results of univariate analysis showed that patients with normal HDL-C had longer progress free survival (PFS) (HR =0.27, 95 ％ CI 0.164-0.444, P ＜ 0.001).The results of multivariate Cox proportional hazard model analysis with sex, pathologic histology, smoking history and mutation type showed that only HDL-C group had a significant difference (P ＜ 0.001).The same results were showed when stratified by sex and smoking history (female: P ＜ 0.001, male: P =0.002;Smoker: P ＜ 0.001, non-smoker: P =0.014).Conclusion Normal pre-treatment serum levels of HDL-C are associated with a better outcome and longer progression-free survival in NSCLC patients treated with EGFR-TKI, which may be a predictive marker for a better response.
